申请人:Janssen Pharmaceutica, N.V.
公开号:US06583141B1
公开(公告)日:2003-06-24
The present invention is concerned with the compounds of formula
wherein m, n and p are each independently 0 or 1 and q is 0, 1, 2, 3, 4 or 5; —A1═A2—A3═A4— is a pyridinylidene, pyridazinylidene, pyrimidinylidene, pyrazinylidene or phenylidene; B represents an amide, ketone or oxadiazole; D represents Ar or Het; Q represents a covalent direct bond or a ketone, —N—, —O—, —CR5R6—, amide ethenyl, imine, sulfonyl, sulfinyl, 3-oxobutenyl, pyrazole, isoxazole or thiazole; L represents Ar or Het; R1 represents hydrogen, halo, hydroxy, C(2-6)alkenyl, C(2-6)alkynyl, C(3-6)cycloalkyl, C(3-6)cycloalkenyl, cyano, guanidine, nitro, NR17R18, an optionally substituted C(1-6)alkyl or C(1-6)alkyloxy; R2 and R3 each independently represent hydrogen, halo, C(1-6)alkyloxy or an optionally substituted C(1-6)alkyl; R5 and R6 each independently represent hydrogen, hydroxy, halo, an optionally substituted C(1-6)alkyl, C(2-6)alkenyl, C(2-6)alkynyl, C(3-6)cycloalkyl, C(3-6)cycloalkenyl, C(1-6)alkyloxy, cyano, (C═O)R25, (C═O)OR16, (SO2)R16, aminocarbonyloxy, aminoC(1-6)alkyl, NR17R18, N3, Ar or Het; or R5 and R6 together with the carbon atom to which they are attached, form an Ar or Het; Ar represents an optionally substituted C(6-14)aryl; Het represents an optionally substituted C(1-14)heterocycle; or a N-oxide, pharmaceutically acceptable addition salt, quaternary amine or stereochemically isomeric form thereof; the processes for their preparation and compositions comprising them. It further relates to their use as a medicine.
本发明涉及以下式中的化合物,其中m、n和p分别独立地为0或1,q为0、1、2、3、4或5;—A1═A2—A3═A4—为吡啶基、吡啶并嗪基、嘧啶基、吡嗪基或苯基;B代表酰胺、酮或噁二唑基;D代表Ar或Het;Q代表共价直接键或酮、—N—、—O—、—CR5R6—、酰胺乙烯基、亚胺、磺酰基、亚砜基、3-氧代丁烯基、吡唑、异噁唑或噻唑;L代表Ar或Het;R1代表氢、卤素、羟基、C(2-6)烯基、C(2-6)炔基、C(3-6)环烷基、C(3-6)环烯基、氰基、胍胺基、硝基、NR17R18、可选择取代的C(1-6)烷基或C(1-6)烷氧基;R2和R3分别独立地代表氢、卤素、C(1-6)烷氧基或可选择取代的C(1-6)烷基;R5和R6分别独立地代表氢、羟基、卤素、可选择取代的C(1-6)烷基、C(2-6)烯基、C(2-6)炔基、C(3-6)环烷基、C(3-6)环烯基、C(1-6)烷氧基、氰基、(C═O)R25、(C═O)OR16、(SO2)R16、氨基羰氧基、氨基C(1-6)烷基、NR17R18、N3、Ar或Het;或R5和R6与它们连接的碳原子一起形成Ar或Het;Ar代表可选择取代的C(6-14)芳基;Het代表可选择取代的C(1-14)杂环;或其N-氧化物、药学上可接受的加合盐、季铵盐或立体化学异构体形式;以及它们的制备方法和包含它们的组合物。进一步涉及它们作为药物的用途。